Skip to main content
. 2022 Aug 9;127(8):1497–1506. doi: 10.1038/s41416-022-01941-0

Fig. 2. Progression-free survival.

Fig. 2

At a median follow-up of 67 months, the estimated 60-month progression-free survival for all patients that started treatment (n = 48) was 23% (95% CI: 12–36%).